昭衍新药前三季度净利8070.61万元

Core Viewpoint - Zhaoyan New Drug (603127) reported a significant decline in revenue for the first three quarters of 2025, indicating potential challenges in its business operations [1] Financial Performance - The company's operating revenue for the first three quarters reached 985 million yuan, representing a year-on-year decrease of 26.23% [1] - The net profit attributable to shareholders was 80.7061 million yuan [1] - The net profit excluding non-recurring items was 29.0447 million yuan [1] Business Segments - The decline in net profit is primarily attributed to the laboratory service business, changes in the fair value of biological assets, and the impact of fund management income [1]